Renaissance Technologies LLC Boosts Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA)

Renaissance Technologies LLC boosted its position in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 77.2% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 166,200 shares of the company's stock after purchasing an additional 72,400 shares during the quarter. Renaissance Technologies LLC owned about 0.44% of Entrada Therapeutics worth $2,874,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. KLP Kapitalforvaltning AS purchased a new stake in shares of Entrada Therapeutics during the 4th quarter worth $36,000. AlphaQuest LLC acquired a new stake in shares of Entrada Therapeutics during the fourth quarter worth about $70,000. Russell Investments Group Ltd. lifted its stake in Entrada Therapeutics by 53,455.6% during the 4th quarter. Russell Investments Group Ltd. now owns 4,820 shares of the company's stock valued at $83,000 after acquiring an additional 4,811 shares during the period. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Entrada Therapeutics in the fourth quarter worth $137,000. Finally, Invesco Ltd. purchased a new position in shares of Entrada Therapeutics during the fourth quarter worth $199,000. 86.39% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a "buy" rating and set a $20.00 price target on shares of Entrada Therapeutics in a research report on Monday, March 31st.

Entrada Therapeutics Stock Up 0.3 %

Shares of NASDAQ TRDA traded up $0.03 during midday trading on Monday, reaching $8.87. 104,304 shares of the stock were exchanged, compared to its average volume of 125,800. The firm has a 50-day simple moving average of $9.85 and a two-hundred day simple moving average of $14.31. Entrada Therapeutics, Inc. has a twelve month low of $7.10 and a twelve month high of $21.79. The firm has a market cap of $333.47 million, a price-to-earnings ratio of 5.58 and a beta of 0.04.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported $0.03 earnings per share for the quarter, beating analysts' consensus estimates of ($0.66) by $0.69. Entrada Therapeutics had a net margin of 25.53% and a return on equity of 16.11%. The company had revenue of $12.25 million during the quarter, compared to analysts' expectations of $11.95 million. Research analysts expect that Entrada Therapeutics, Inc. will post 1.12 EPS for the current fiscal year.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.